SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 2,400 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 2,400 shares of the firm’s stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $4.87, for a total transaction of $11,688.00. Following the completion of the transaction, the insider directly owned 281,452 shares in the company, valued at $1,370,671.24. This represents a 0.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $13,095.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total transaction of $2,912.32.

SOPHiA GENETICS Trading Down 0.8%

SOPH stock opened at $4.86 on Thursday. The company has a market capitalization of $332.86 million, a PE ratio of -9.53 and a beta of 1.04. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70. The firm’s 50-day moving average is $4.77 and its 200 day moving average is $4.68. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The company had revenue of $21.71 million during the quarter, compared to analysts’ expectations of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. On average, research analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC grew its holdings in SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares in the last quarter. Alta Wealth Advisors LLC bought a new position in SOPHiA GENETICS during the 3rd quarter worth about $6,708,000. Royce & Associates LP bought a new position in SOPHiA GENETICS during the 4th quarter worth about $2,009,000. Finally, 1492 Capital Management LLC bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at about $973,000. 31.59% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. BTIG Research reiterated a “buy” rating and set a $7.00 target price on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Guggenheim increased their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $7.00.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: CEO Jurgi Camblong executed two Rule 10b5‑1 sales (2,600 and 2,500 shares at ~$4.85–4.86). CEO still holds ~3.7M shares. SEC filing
• Neutral Sentiment: CFO George Cardoza reported multiple small sales (~2,520; 2,413 shares) under a 10b5‑1 plan to cover taxes; remaining holdings stay large (~292–295k shares). SEC filing
• Neutral Sentiment: CTO Abhimanyu Verma sold several tranches (2,519; 1,030 shares) under a 10b5‑1 plan; still owns ~204–205k shares. SEC filing
• Neutral Sentiment: President Ross Muken and other senior managers (Philippe Menu, Zhenyu Xu, Manuela Valente, Well Daan Van, Kevin Puylaert) reported multiple planned sales of ~600–2,700 shares each to cover tax obligations; each filing cites Rule 10b5‑1 plans. Representative filings: Menu, Xu, Valente. Menu SEC filing
• Neutral Sentiment: Collectively the insider sales are modest relative to total insider holdings and were executed under pre‑arranged plans (tax withholding stated as purpose), which reduces negative informational signal but can still create short-term selling pressure.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.